Compare · IDXX vs ORKA
IDXX vs ORKA
Side-by-side comparison of IDEXX Laboratories Inc. (IDXX) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IDXX and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- IDXX is the larger of the two at $45.00B, about 13.2x ORKA ($3.42B).
- Over the past year, IDXX is up 30.5% and ORKA is up 568.3% - ORKA leads by 537.8 points.
- ORKA has been more active in the news (6 items in the past 4 weeks vs 2 for IDXX).
- IDXX has more recent analyst coverage (23 ratings vs 11 for ORKA).
- Company
- IDEXX Laboratories Inc.
- Oruka Therapeutics Inc.
- Price
- $565.97+0.89%
- $68.97+2.03%
- Market cap
- $45.00B
- $3.42B
- 1M return
- -1.66%
- +57.38%
- 1Y return
- +30.49%
- +568.31%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1991
- News (4w)
- 2
- 6
- Recent ratings
- 23
- 11
IDEXX Laboratories Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Latest IDXX
- Citigroup initiated coverage on IDEXX Labs with a new price target
- IDEXX Laboratories to Release 2026 First Quarter Financial Results
- IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma
- SEC Form DEFA14A filed by IDEXX Laboratories Inc.
- SEC Form DEF 14A filed by IDEXX Laboratories Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by IDEXX Laboratories Inc.
- IDEXX Laboratories Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form PRE 14A filed by IDEXX Laboratories Inc.
- EVP, GC & Corporate Secretary Underberg Sharon E. exercised 197 shares at a strike of $505.53, increasing direct ownership by 3% to 7,138 units (SEC Form 4)
- Executive Vice President Hunt Nimrata sold $1,115,577 worth of shares (1,758 units at $634.57), decreasing direct ownership by 9% to 18,141 units (SEC Form 4)
Latest ORKA
- Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
- SEC Form 424B7 filed by Oruka Therapeutics Inc.
- SEC Form DEFA14A filed by Oruka Therapeutics Inc.
- SEC Form DEF 14A filed by Oruka Therapeutics Inc.
- SEC Form 4 filed by Goncalves Joana
- SEC Form EFFECT filed by Oruka Therapeutics Inc.
- SEC Form S-3 filed by Oruka Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Oruka Therapeutics Inc.
- Chief Executive Officer Klein Lawrence Otto sold $71,408 worth of shares (1,729 units at $41.30), decreasing direct ownership by 0.19% to 927,309 units (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun sold $16,313 worth of shares (395 units at $41.30), decreasing direct ownership by 2% to 18,863 units (SEC Form 4)